COVID-19: Reimagining Biotech in 2021
July 8, 2020  |  8:00 AM PDT  |  11:00 AM EDT

As global biopharma leaders make contingency plans and build scenarios for a COVID-19 world, many are left to wonder: What will 2021 look like?

In Part 2 of this exclusive webinar series, BioCentury and McKinsey & Co. discuss key findings from a recent BioCentury industry survey about how 2021 will look different for biopharma companies. From budgeting, to clinical trials, to deals and financings, to supply chains, COVID-19 has fundamentally changed how the biopharma industry will operate in 2021, and beyond.

Following the initial discussion, BioCentury and McKinsey will convene a panel of biotech C-Suite to discuss the survey findings and what industry should expect in 2021.

Session Chairs

Fishburn_Simone.jpg
Simone Fishburn, Ph.D.
VP & Editor in Chief
BioCentury Inc.
da-Silva_Jorge_Santos_headshot.jpeg
Jorge Santos da Silva
Partner
McKinsey & Co.

Panelists:

John_Cox_Headshot.jpeg
John Cox
CEO
Repertoire Immune Medicines
2020-1-20 Bahija Jallal photo.jpg
Bahija Jallal, Ph.D.
CEO
Immunocore
Scott K-headshot 100 px2020.jpg
Scott Koenig, M.D., PH.D.
President & CEO
MacroGenics
John Oyler.png
John Oyler
Chairman, Co-Founder & CEO
BeiGene



Hosted by:

BioCentury_Web_Logo_Teal_400w.jpg


In collaboration with:

McK_ScriptMark_CMYK_McKDeepBlue.jpg
Webinar Registration